

# The Effect of Macrophages on Fibroblast Activity and Lesion Development in Mouse Models of Endometriosis

---

Mohammad Zahied Johan  
Discipline of Obstetrics and Gynaecology  
School of Paediatrics and Reproductive  
Health

Research Centre for Reproductive Health,  
Robinson Institute, Adelaide, Australia

November 2013



# Table of Contents

---

List of Tables .....	9
Table of Figures .....	10
Table of Abbreviations .....	12
Abstract .....	15
Declaration .....	17
Publications and conference presentations.....	18
Acknowledgements .....	19
Chapter 1 .....	21
1.1 Introduction.....	21
1.1.1 The pathogenesis of endometriosis .....	21
1.1.1.1 Origin of endometriosis .....	22
1.1.1.2 Other theories of endometriosis pathogenesis.....	25
1.1.2 Current treatments for endometriosis .....	27
1.1.2.1 Medical therapy .....	27
1.1.2.2 Conclusion .....	29
1.1.3 Ectopic endometrial implantation in endometriosis.....	30
1.1.3.1 Escaping immune surveillance .....	32
1.1.3.2 Formation of blood vessels.....	34
1.1.4 Macrophage activity in endometriosis .....	35
1.1.4.1 Inflammatory macrophages and initiation of endometriosis.....	35
1.1.4.2 Macrophage recruitment into endometriosis tissue.....	36
1.1.4.3 Macrophage plasticity.....	38
1.1.4.4 Importance of macrophage in tissue remodelling.....	43
1.1.4.5 Conditional macrophage ablation studies .....	45
1.1.5 Myofibroblast differentiation during endometriosis establishment .....	46

1.1.5.1	The origins and characteristics of myofibroblasts .....	46
1.1.5.2	Fibroblast-to-myofibroblast differentiation is mediated by growth factors .....	47
1.1.5.3	Epithelial-mesenchymal transition (EMT) as the source of myofibroblast .....	48
1.1.5.4	Possible macrophage-myofibroblast transformation.....	49
1.1.5.5	Myofibroblasts in endometriosis .....	50
1.1.5.6	Conclusion .....	51
1.1.6	TGFB1 is the main mediator in endometriosis development .....	51
1.1.6.1	Latent TGFB activation .....	53
1.1.6.2	TGFB1 involvement in endometriosis pathogenesis .....	54
1.1.6.3	Macrophage activation by TGFB1 .....	55
1.1.6.4	TGFB secretion by macrophages .....	56
1.1.6.5	TGFB in ECM remodelling .....	56
1.1.6.6	<i>In vivo Tgfb1</i> -null mouse model.....	57
1.1.6.7	Macrophages in <i>Tgfb1</i> -null mutant mice .....	58
1.1.6.8	Other isoforms of TGFB1.....	59
1.2	Conclusion .....	60
1.3	Hypothesis .....	61
	Chapter 2 .....	62
2.1	Background.....	62
2.1.1	Models to study endometriosis .....	62
2.1.1.1	Primate models.....	62
2.1.1.2	Immunocompetent rodent models .....	63
2.1.1.3	Chicken chorioallontoic membrane (CAM) .....	65
2.1.1.4	Immunodeficient mouse models.....	66
2.1.1.5	Genetically manipulated mouse models .....	67
2.1.1.6	Estrogenised rodent models.....	70
2.1.2	Rationale of the methods .....	71

2.1.3	Time-point study in endometriosis models .....	72
2.1.4	Conclusion .....	73
2.2	Materials and Methods .....	75
2.2.1	Endometrium biopsy .....	75
2.2.1.1	Collection of human endometrial tissues .....	75
2.2.1.2	Endometrial tissue preparation .....	76
2.2.2	Animal models .....	76
2.2.2.1	eGFP-CSF-1R (MacGreen) mouse .....	76
2.2.2.2	Animal husbandry and handling .....	78
2.2.2.3	pEGFP-N1 and <i>Tgfb1</i> genotyping and SCID phenotyping .....	79
2.2.3	Mouse preparation .....	83
2.2.3.1	Ovariectomy .....	83
2.2.3.2	<i>In vivo</i> injection of human endometrial tissues .....	84
2.2.3.3	Harvesting endometriosis-like lesions from experimental mice .....	84
2.2.4	Histology and immunohistochemistry .....	86
2.2.4.1	Tissue preparations .....	86
2.2.4.2	Haematoxylin and eosin staining .....	86
2.2.4.3	Antibodies and lectins .....	86
2.2.4.5	Immunohistochemistry and immunofluorescent conditions .....	90
2.2.4.7	Morphometric analyses .....	94
2.2.4.8	Statistical analyses .....	95
Chapter 3	.....	102
3.1	Introduction .....	102
3.1.1	Transforming growth factor beta 1 .....	102
3.1.2	<i>Tgfb1</i> -null mutant mice .....	104
3.1.3	Tissue remodelling in endometriosis .....	105
3.2	Materials and methods .....	106

3.3	Results .....	106
3.3.1	Patient demographics .....	106
3.3.2	Endometriosis-like lesion development .....	106
3.3.3	Morphometric analyses .....	107
3.3.4	Macrophage abundance in periphery.....	108
3.3.5	Myofibroblast abundance .....	109
3.3.6	Cell proliferation and blood vessel density.....	109
3.4	Discussion .....	120
3.4.1	Summary of findings .....	120
3.4.2	Validation of models .....	121
3.4.3	Morphology of the endometriosis-like lesions .....	123
3.4.4	Lower macrophage abundance in lesions from TGFB1 deficient mice .....	125
3.4.5	Myofibroblast reduction in the absence of host TGFB1 .....	127
3.4.6	Cell proliferation and blood vessel were not affected in lesions from host deficient in TGFB1.....	128
3.4.7	Limitations of our model.....	131
3.4.7.1	The absence of menstrual cycle .....	131
3.4.7.2	The use of non-menstrual tissues.....	132
3.4.7.3	Short duration.....	132
3.4.7.4	Species-specific cellular interactions.....	132
3.4.8	Clinical importance.....	133
3.5	Conclusions.....	134
	Chapter 4 .....	135
4.1	Introduction.....	135
4.1.1	Rationale for this study .....	135
4.1.2	Macrophage markers .....	137
4.1.2.1	MHC class II.....	138

4.1.2.2	Inducible nitric oxide synthase (iNOS).....	140
4.1.2.3	Arginase 1 .....	141
4.1.2.4	Scavenger receptor.....	143
4.1.2.5	Macrophages in healing and repair process.....	143
4.1.2.6	Macrophage polarisation in human tissues .....	145
4.1.2.7	Macrophage abnormalities in women with endometriosis .....	145
4.1.3	MacGreen mice .....	147
4.1.4	Summary .....	148
4.2	Materials and methods .....	148
4.3	Results .....	149
4.3.1	Patient demographics .....	149
4.3.2	Development of endometriosis-like lesions in MacGreen/SCID mice.....	149
4.3.3	Weight and size of endometriosis-like lesions.....	151
4.3.4	Histology of endometriosis-like lesions .....	152
4.3.5	Immunofluorescent staining to localise macrophage activation markers, collagen and TGFB1 .....	153
4.3.5.1	Antibody binding specificity .....	153
4.3.5.2	Macrophage activation markers.....	154
4.3.5.3	Type 1 collagen .....	158
4.3.5.4	Active TGFB1 staining .....	159
4.4	Discussion .....	174
4.4.1	Glandular fraction was increased during endometriosis development .....	175
4.4.2	Macrophage phenotypes dynamically changed during endometriosis development.....	179
4.4.2.1	The role of iNOS during early stage of endometriosis development .....	180
4.4.2.2	MHC class II in endometriosis-like lesion inflammation.....	182
4.4.2.3	Arginase 1 expression by macrophages .....	183

4.4.2.4	Scavenger receptor A CD204 in endometriosis-like lesion development....	185
4.4.3	Possible factors mediating macrophage polarisation in endometriosis.....	186
4.4.3.1	Iron homeostasis .....	187
4.4.3.2	Apoptosis cells .....	188
4.4.3.3	Hypoxia .....	188
4.4.3.4	Other factors that could contribute to macrophage polarisation.....	190
4.4.4	The role of macrophages in collagen deposition.....	191
4.4.5	The role of collagen in macrophage functions .....	192
4.5	Conclusions.....	194
Chapter 5.....		196
5.1	Introduction.....	196
5.1.1	TGFB1 and macrophages .....	196
5.1.2	Macrophage phenotypes during cellular inflammation and repair .....	196
5.1.3	Summary .....	198
5.2	Materials and methods .....	199
5.3	Results .....	199
5.3.1	Patient demographics .....	199
5.3.2	Weight of endometriosis like lesions.....	200
5.3.3	Histology of the lesions.....	200
5.3.4	Immunofluorescent staining of endometriosis-like lesions.....	201
5.3.4.1	Assessment of non-specific antibody binding.....	201
5.3.4.2	Species specificity of antibodies .....	202
5.3.4.3	F4/80+ macrophage population .....	202
5.3.4.4	Inflammatory macrophage markers.....	203
5.3.4.5	Tissue repair macrophage markers .....	203
5.4	Discussion .....	215

5.4.1	Macrophage infiltration was impaired in lesions from <i>Tgfb1</i> -null mutant mice	216
5.4.2	Inflammatory markers were altered in the lesions with host deficient TGFB1...	217
5.4.3	Alternatively activated markers were differently regulated in lesions from <i>Tgfb1</i> -null mutant mice .....	219
5.4.4	Collagen type 1 expression was reduced in the lesions from <i>Tgfb1</i> -null mice ...	222
5.4.5	Limitations of this study.....	224
5.5	Conclusions.....	225
Chapter 6 .....		227
6.1	Introduction.....	227
6.1.1	TGFB1 is critical for a normal tissue development .....	228
6.1.2	TGFB1-regulated modelling of endometriosis-like lesions.....	228
6.1.2.1	Glandular area .....	228
6.1.2.2	Macrophage recruitment .....	229
6.1.2.3	Myofibroblast activity.....	230
6.2	Macrophages have different phenotypes.....	230
6.2.1	Inflammatory macrophage markers .....	230
6.2.2	Tissue repair .....	231
6.3	TGFB1-deficiency alters macrophage phenotypes .....	232
6.4	Collagen type 1 .....	232
6.5	Future directions .....	234
6.5.1	Potential treatments for endometriosis .....	235
6.6	Summary.....	236
References.....		238
Appendix.....		264



# List of Tables

---

Table 2 A: PCR primers for mouse genotyping.....	81
Table 2 B: Primary antibodies for paraffin sections .....	88
Table 2 C: Primary antibodies for PFA/sucrose-fixed frozen sections .....	89
Table 2 D: Primary antibodies for frozen sections .....	90
Table 3. 1: Clinical data of the recruited patients for eutopic endometrial tissue collection .....	111
Table 4. 1: Clinical data of the recruited patients for eutopic endometrial tissue collection .....	160
Table 4. 2: The number of CSF-1R-eGFP (MacGreen) mice receiving tissues from each patient and the percentage of mice developed lesions at the end of time points .....	161
Table 4. 3: The number of MacGreen mice allocated for each time point.....	162
Table 5. 1: Clinical data of the recruited patients for eutopic endometrial tissue collection .....	205

# Table of Figures

---

## Chapter 1

Figure 1 A: Theoretical mechanisms of endometriosis pathogenesis. ....	30
Figure 1 B: A simplistic view of macrophage activation and their associated functions. ....	40
Figure 1 C: TGFB molecular pathways, which involve the release of mature TGFB proteins from LAP.....	53

## Chapter 2

### Results

Figure 2. 1: The physical difference between a <i>Tgfb1</i> <sup>-/-</sup> female (A) and a wildtype ( <i>Tgfb1</i> <sup>+/+</sup> ) littermate (B) at the age of 6 weeks. ....	97
Figure 2. 2: Gel electrophoresis for <i>Tgfb1</i> genotyping.....	98
Figure 2. 3: Genotyping eGFP transgene by PCR.....	99
Figure 2. 4: Gel electrophoresis of <i>Alu1</i> -digested <i>prkdc</i> products of SCID x MacGreen mice to detect for the presence of SCID-point mutation. ....	100
Figure 2. 5: The percentage of T lymphocyte-specific CD3e-positive cells of <i>Prkdc</i> <sup>Scid</sup> mouse (A) and SCID x MacGreen progeny (C).....	101

## Chapter 3

### Results

Figure 3. 1: Gross morphology of endometriosis-like lesions photographed at day 10 after tissue injection.....	112
Figure 3. 2: Morphology of endometriosis-like lesions as stained using Haematoxylin and Eosin. ....	113
Figure 3. 3: Glandular morphology of endometriosis-like lesions from <i>Tgfb1</i> <sup>+/+</sup> and <i>Tgfb1</i> <sup>-/-</sup> mice.....	114
Figure 3. 4: Isotype and species-specific controls for each immunostaining condition. ....	115
Figure 3. 5: F4/80 immunostaining to localise murine macrophages in <i>Tgfb1</i> -wildtype (C) and -knockout (D) lesions. ....	116
Figure 3. 6: Alpha smooth muscle actin ( $\alpha$ SMA) immunostaining to localise myofibroblasts in <i>Tgfb1</i> -wildtype (C) and -knockout (D) lesions.....	117
Figure 3. 7: BrdU immunostaining to localise proliferating cells in <i>Tgfb1</i> -wildtype (B and C) and -knockout (E and F) lesions in glandular epithelium (B and E) and stroma (C and F).....	118
Figure 3. 8: von Willebrand Factor (vWF) immunostaining to localise blood vessels in <i>Tgfb1</i> -wildtype (C) and -knockout (D) lesions.....	119

## Chapter 4

Figure 4 A: Nitric oxide synthase and arginase pathways in a macrophage. M1-induced cytokines such as IFN $\gamma$ and TNF $\alpha$ drive the expression of inducible nitric oxide synthase (iNOS).....	141
---	-----

## Results

Figure 4. 1: Endometriosis-like lesions development in MacGreen/SCID mice.....	163
Figure 4. 2: Haematoxylin and eosin staining of endometriosis-like lesions. ....	164
Figure 4. 3: Infiltration of macrophages (eGFP-positive cells) into endometriosis-like lesions at four time points.....	165
Figure 4. 4: Isotype-matched control for each immunostaining condition. ....	166
Figure 4. 5: Species specificity for each primary antibody tested on murine and human tissues. ....	167
Figure 4. 6: MHC class II was localised in association with eGFP-positive macrophages. ....	168
Figure 4. 7: Inducible nitric oxide synthase (iNOS) expression was localised with eGFP-positive cells. ....	169
Figure 4. 8: Arginase 1 was identified in association with eGFP-positive macrophages. ....	170
Figure 4. 9: Scavenger receptor A, CD204 localised to eGFP-positive cells.....	171
Figure 4. 10: Collagen type 1 deposition in endometriosis-like lesions.....	172
Figure 4. 11: TGFB1 localisation in association with eGFP macrophages in endometriosis-like lesions at day 10.....	173

## Chapter 5

### Results

Figure 5. 1: Endometriosis-like lesions at day 10 from <i>Tgfb1</i> -null mutant mice ( <i>Tgfb1</i> <sup>-/-</sup> ) and wildtype control ( <i>Tgfb1</i> <sup>+/+</sup> ). ....	206
Figure 5. 2: Isotype-matched control for each immunostaining condition. ....	207
Figure 5. 3: Species specificity for each primary antibody as tested on murine and human tissues.....	208
Figure 5. 4: Infiltration of macrophages (F4/80+ cells) into endometriosis-like lesions at day 10 from <i>Tgfb1</i> <sup>+/+</sup> and <i>Tgfb1</i> <sup>-/-</sup> mice.....	209
Figure 5. 5: Expression of MHC class II macrophages in endometriosis-like lesions at day 10 from <i>Tgfb1</i> <sup>+/+</sup> and <i>Tgfb1</i> <sup>-/-</sup> mice.....	210
Figure 5. 6: Inducible nitric oxide synthase (iNOS)-positive cells in endometriosis-like lesions at day 10 from <i>Tgfb1</i> <sup>+/+</sup> and <i>Tgfb1</i> <sup>-/-</sup> mice. ....	211
Figure 5. 7: Infiltration of arginase 1 (Arg1)-positive cells into endometriosis-like lesions at day 10 from <i>Tgfb1</i> <sup>+/+</sup> and <i>Tgfb1</i> <sup>-/-</sup> mice.....	212
Figure 5. 8: Scavenger receptor A (CD204) expression in endometriosis-like lesions at day 10 from <i>Tgfb1</i> <sup>+/+</sup> and <i>Tgfb1</i> <sup>-/-</sup> mice.....	213
Figure 5. 9: Collagen type 1 deposition in endometriosis-like lesions.....	214

# Table of Abbreviations

Abbreviation	Description
$\alpha$ SMA	Alpha smooth muscle actin
$\beta$ 2m	Beta-2-microglobulin
$\mu$ L	Microlitre
$\mu$ m	Micrometer
AcLDL	Acetyl low density lipoprotein
BAX	BCL-2 associated X protein
BCL-2	B-cell lymphoma 2
bp	Base pair
BrdU	5-bromo-2'-deoxyuridine
BSA	Bovine serum albumin
CAM	Chorioallantoic membrane
CCL (e.g. CCL17)	Chemokine (C-C motif) ligand
CCR1	Chemokine (C-C motif) receptor 1
COCs/COC	Combined oral contraceptives
CSF-1/Csf-1	Colony stimulating factor-1
CSF-1R	Colony stimulating factor-1 receptor
CXCL (e.g. CXCL13)	Chemokine (C-X-C motif) ligand
CYP	Cytochrome
CYR61	Cysteine-rich, angiogenic inducer, 61
DAB	3,3'-diaminobenzidine
DAPI	4',6-diaminido-2-phenylindole dihydrochloride
dNTPs	Deoxynucleotide triphosphates
DT	Diphtheria toxin
ECM	Extracellular matrix
eGFP	Enhanced green fluorescent protein
EMMPRIN	Extracellular matrix metalloproteinase inducer
EMT	Epithelial-mesenchymal transition
eNOS	Endothelial nitric oxide synthase
FACS	Fluorescence-activated cell sorting

FAK	Focal adhesion kinase
FdU	2'-fluoro-2'-deoxyuridine
Fizz1	Resistin-like molecule alpha 1
Flt1	Fms-related tyrosine kinase 1
FSH	Follicle-stimulating hormone
GFP	Green fluorescent protein
GM-CSF	Granulocyte macrophage colony-stimulating factor
GnRH	Gonadotropin-releasing hormone
H&E	Haematoxylin and eosin
HIF-1 $\alpha$	Hypoxia inducible factor-1 $\alpha$
HLA (e.g. HLA-DR)	Human leukocyte antigen (MHC)
HRP	Horseradish peroxidase
HSV	Herpes simplex virus
ICAM-1	Intercellular adhesion molecule-1
IFN (e.g. IFN $\gamma$ )	Interferon
Ig	Immunoglobulin
IL (e.g. IL-1)	Interleukin
iNOS	Inducible nitric oxide synthase
IVF	<i>In vitro</i> fertilisation
KC	Keratinocyte chemoattractant
LAP	Latency-associated peptide
LH	Luteinising hormone
LPS	Lipopolysaccharide
Ly6C	Lymphocyte antigen 6C
M0	Unpolarised macrophage
M1	Classically activated macrophage
M2	Alternatively activated macrophage
MCP-1	Monocyte chemoattractant protein -1
M-CSF	Macrophage-colony stimulating factor
MDSC	Myeloid derived suppressor cell
MHC (e.g. MHC class II)	Major histocompatibility complex
MIF	Macrophage inhibitory factor
MIP (e.g. MIP-1 $\alpha$ )	Macrophage-inflammatory protein

mL	Millilitre
MMP (e.g. MMP-1)	Matrix metalloproteinase
Msr1	Macrophage scavenger receptor 1
MUC1	Mucin 1, Cell surface associated
NC	Negative control
<i>Neo</i>	Neomycin
<i>Neo<sup>r</sup></i>	Neomycin resistance gene
NO	Nitric oxide
NOS (e.g. Nos2)	Nitric oxide synthase
OCT	Optimum cutting temperature compound
OSE	Ovarian surface epithelium
PBS	Phosphate-buffered saline
PCR	Polymerase chain reaction
PE	Phycoerythrin
PFA	Paraformaldehyde
PPAR $\gamma$	Peroxisome proliferator-activated receptor $\gamma$
<i>Prkdc</i>	Protein kinase, DNA-activated, catalytic polypeptide
RANTES	Regulated on activation, normal T cell expressed and secreted (CCL-5)
rASRM	Revised American Fertility Society (AFS) score
SCID	Severe combined immunodeficiency
SR-A	Class A scavenger receptor
TAE buffer	Tris-acetate-EDTA buffer
TAM	Tumor-associated macrophage
TCDD	2, 3, 7, 8-Tetrachlorodibenzo- <i>p</i> -dioxin (dioxin)
TCR	T cell receptor
TEM	Tie2-expressing monocytes/macrophage
TGFB/Tgfb (e.g. TGFB1)	Transforming growth factor beta
TNF $\alpha$	Tumor necrosis factor $\alpha$
TUNEL	Terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling
uPA	Urokinase-type plasminogen activator
VEGF	Vascular endothelial growth factor
vWF	von Willebrand Factor

# Abstract

---

Endometriosis is a gynaecological disease characterised by the growth of endometrial tissues at ectopic sites. Although this disease affects 10-15% of women worldwide, its pathogenesis is still poorly understood.

Human eutopic endometrial tissues were xenografted into two strains of immunodeficient (SCID) mice with 1) a null mutation for *Tgfb1* gene (*Tgfb1*<sup>-/-</sup>) and 2) macrophage-restricted expression of GFP (CSF-1R-eGFP/MacGreen). The resulting xenografts were collected at day 10 post-implantation for *Tgfb1*<sup>-/-</sup> mice and at days 4, 7, 10 and 14 in a time course study using MacGreen mice. Five xenografts collected from *Tgfb1*<sup>-/-</sup> mice were embedded in paraffin and were compared to *Tgfb1*<sup>+/+</sup> tissues for macrophage number, myofibroblast staining ( $\alpha$ SMA), proliferating cell number and blood vessel density. Another five xenografts from *Tgfb1*<sup>-/-</sup> mice and all xenografts from MacGreen mice were frozen in OCT to assess macrophage markers, MHC class II, iNOS, arginase 1 and scavenger receptor A, and collagen type 1.

Using *Tgfb1*<sup>-/-</sup>/SCID mice, we demonstrated that in the absence of host TGFB1, development of endometriosis-like lesions was suppressed and their glandular area was reduced. We also observed lower numbers of macrophages and a reduced density of myofibroblasts in the lesions from *Tgfb1*<sup>-/-</sup> mice.

Using MacGreen/SCID mice, we followed the changes in macrophage phenotypes during endometrial xenograft development. Macrophages were phenotypically diverse and pre-dominantly expressed the inflammatory markers MHC class II and iNOS at the early stage of disease development (days 4 and 7). The tissue repair marker, arginase

1, appeared later in lesion development at day 7. Meanwhile, another macrophage marker for tissue healing, scavenger receptor A was higher at day 14 than at the earlier time point. In addition, collagen type 1 staining increased throughout lesion development with its highest intensity evident at day 14.

In the absence of host TGFB1, the number of cells expressing MHC class II was significantly reduced at day 10 compared to the lesions from the wildtype controls. Similarly, iNOS-positive cells were decreased in lesions from *Tgfb1*<sup>-/-</sup> mice. The number of arginase 1-positive cells was not altered in the lesions from *Tgfb1*<sup>-/-</sup> mice, suggesting TGFB1 was not critical for arginase 1 expression in these tissues. The abundance of cells expressing scavenger receptor A was significantly reduced in lesions from *Tgfb1*<sup>-/-</sup> mice. A reduction in the collagen type 1 density was detected in the lesions which developed in a TGFB1-deficient environment.

These studies show that host-derived TGFB1 is critical during endometriosis-like lesion development. The presence of this cytokine altered the abundance of infiltrating macrophages and myofibroblasts. In a time course study, macrophages shifted from inflammatory phenotypes at the early stage to an alternatively activated phenotype associated with tissue healing at later stages. The secretion of collagen type 1 fibres was increased and this was associated with the transition to a remodelling macrophage population. Lesion development appeared to be interrupted when lesions were grown in a TGB1-deficient environment resulting in diminished lesion weight. The understanding behind macrophage activation in endometriotic lesions may provide new information on how endometriosis may be interrupted by moderating macrophage behaviours.



# Declaration

---

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution to Mohammad Zahied Johan and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

The author acknowledges that copyright of published works contained within this thesis (as listed in Publications section) resides with the copyright holder(s) of those works.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue, the Australasian Digital Theses Program (ADTP) and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Name :.....

Signature:.....

Date :.....

# Publications and conference presentations

---

Publications and conference presentation arising from this thesis

1. Hull, M.L., Johan, M.Z., Hodge, W.L., Robertson, S.A., Ingman, W.V., *Host-Derived TGFB1 Deficiency Suppresses Lesion Development in a Mouse Model of Endometriosis*, The American Journal of Pathology, 2012, vol. 180 (3), p.880-887
2. Johan, M.Z., Ingman, W.V., Robertson, S.A., Hull, M.L., *Lesion Weight and Glandular Development are Suppressed in a TGFB1 Deficient Mouse Model of Endometriosis*, 41<sup>st</sup> Society of Reproductive Biology Annual Conference, 29<sup>th</sup> August-1<sup>st</sup> September 2010, Sydney, Australia (Abstract 133) – Oral presentation
3. Johan, M.Z., Ingman, W.V., Robertson, S.A., Hull, M.L., *Suppression of Endometriosis-like Lesion Development in a TGFB1<sup>-/-</sup> SCID Mouse Model of Endometriosis*, 11<sup>th</sup> World Congress on Endometriosis, 4<sup>th</sup> -7<sup>th</sup> September 2011, Montpellier, France (Abstract FC5-3) – Poster presentation
4. Johan, M.Z., Ingman, W.V., Robertson, S.A., Hull, M.L., *Activations Status of Macrophages in Lesions from a MacGreen/SCID Mouse Model of Endometriosis*, 60<sup>th</sup> Annual Meeting Society for Gynecologic Investigation, 20<sup>th</sup>-23<sup>rd</sup> March 2013, Orlando, Florida, USA (Abstract T-109) – Poster presentation
5. Johan, M.Z., Ingman, W.V., Robertson, S.A., Hull, M.L., *Altered macrophage phenotypes and collagen level in Tgfb1<sup>-/-</sup>/SCID mouse model of endometriosis*, Society of Reproductive Biology Annual Conference, 25<sup>th</sup> -28<sup>th</sup> August 2013, Sydney, Australia (Abstract) – Oral presentation

# Acknowledgements

---

This thesis would not have been possible without feedback and input from my supervisors, Dr Louise Hull, Prof Sarah Robertson and A/Prof Wendy Ingman. I am grateful for their willingness to share knowledge and experience, which improved my journey tremendously. Within the Endometriosis Research Group, I would like to thank Dr Jonathan McGuane and Dr Zhao Wang for sharing their scientific knowledge.

I would also like to thank patients, who participated in this study, surgeons and staff at The Queen Victoria Operating Suite, Women's and Children's Hospital, Adelaide, who assisted in tissue collection. I would like to acknowledge Mrs Helen Alvino for her assistance in ethics applications and staff at Laboratory Animal Services for their help with animal handling. Without them, the experiments would never have been completed.

I am most grateful for the financial support from The University of Adelaide through Adelaide Graduate Fee Scholarship. I would like to acknowledge RED team, in particular Dr Michelle Picard, Dr Robyn Groves and Mrs Janet Simpson for their support in writing and improving my English in general. I would like to express my gratitude to Robinson Institute and School of Paediatrics and Reproductive Health for providing financial assistance to attend conferences and support during candidature. I would like to thank HDR team, in particular Dr Carmela Ricciardelli, Mrs Kay Govin and Mrs Pat Grant for organising annual review and providing support wherever needed.

Above all, I am more than grateful to have my family and friends for their continuing support and compassion. Thanks to Jason Robinson for his patience and for being a good listener.